CA Healthcare Acquisition Corp. CAHC
9.94 0.00 (+0.00%)
Apr 24, 2025, 3:47 PM EDT
9.57 Day range 10.38
52-week range unavailable
- Market cap
- 171.46M
- Shares out
- 14.38M
- Forward P/E
- -25.49
- Volume
- 1.38M
- Open
- 10.09
- Previous close
- 9.94
- Day's range
- 9.57 – 10.38
- Analysts
- Strong Buy
- Price target
- 14.75 (+48.4%)
No chart data for this range yet.
Key statistics
- Enterprise value
- 145.14M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 28.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 623.68K
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 10.05%
- 50-day average
- 9.95
- 200-day average
- 9.88
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 14.75
Ratings (-1m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.38.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 31, 2021 | Ladenburg Thalmann | init | — | Buy |
About CA Healthcare Acquisition Corp.
CA Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more operating businesses. CA Healthcare Acquisition Corp. was founded in 2020 and is based in Boston, Massachusetts.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
- Website
- cahcspac.com
News
LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp. 
CA Healthcare Acquisition Corp. and LumiraDx Limited Announce Effectiveness of Registration Statement and September 28, 2021 Special Meeting to Approve Business Combination 
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2021 
LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation Point-of-Care Diagnostics 
LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation Point-of-Care Diagnostics 
LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare Acquisition Corp
Your note
Sign in to keep a note on CAHC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Hudson Bay Capital Management LP | 6.20% | 713,113 | 7.04M | Jun 29, 2021 |
| Millennium Management LLC | 5.56% | 639,195 | 6.31M | Jun 29, 2021 |
| Mangrove Partners | 4.35% | 500,000 | 4.93M | Jun 29, 2021 |
| Marshall Wace LLP | 4.22% | 484,852 | 4.79M | Jun 29, 2021 |
| Exos Asset Management, LLC | 4.02% | 462,126 | 4.56M | Jun 29, 2021 |
| Falcon Edge Capital, LP | 3.97% | 456,596 | 4.51M | Jun 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AQR Funds-AQR Diversified Arbitrage Fd | 0.72% | 82,600 | 815.26K | Jun 29, 2021 |
| Fidelity NASDAQ Composite Index Fund | 0.22% | 24,829 | 244.81K | Jul 30, 2021 |
| Investment Managers Ser Tr-Vivaldi Merger Arbitrage Fd | 0.11% | 12,296 | 121.36K | Jun 29, 2021 |